What started out six years ago as a local ‘passion project’ for Bayer to collaborate with Berlin’s digital health scene has grown into a truly global programme.
Novartis has filed its ophthalmology drug brolucizumab with the US regulator, a potentially strong competitor in the tough market for drugs for the degenerative eye condition wet AMD.
Radiopharmaceuticals are already well established in imaging technology for a range of diseases – but their use to deliver a lethal dose of radiation to cancer cells is also gaining increas
Bayer and Johnson & Johnson have agreed to settle more than 25,000 US lawsuits worth more than $775 million alleging that blockbuster blood thinner Xarelto caused unstoppable and someti